clinical trial · NCT05844332
LUTATHERA Injection General Use Result Survey
Somatostatin Receptor-positive Neuroendocrine TumorLUTATHERA
brief summary
This study was a multicenter observational study with a central registration system and all-case surveillance system without a control group.
started
Dec 17, 2021
primary completion
Jun 27, 2024
completion
Jun 27, 2024
last updated
Dec 22, 2025
detailed description
From the date of the first dose of this drug until 40 weeks after the date of the last dose (64 weeks if 4 doses are administered 8 weeks apart).
For patients who discontinue treatment with this drug during the observation period, necessary variables were examined until 40 weeks after the last dose of this drug during the observation period and recorded in the case report forms (CRF).
official title
LUTATHERA Injection General Use Result Survey (Somatostatin Receptor-positive Neuroendocrine Tumor, CAAA601A11401)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol